Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
Logo Image
News|Podcasts|May 8, 2026 (Updated: May 8, 2026)

The BioPharm Brief: Bispecifics, Biocatalysis, and Dual-Pathway Therapies

Today’s BioPharm Brief covers next-generation immunotherapy, scalable peptide manufacturing, and Johnson & Johnson’s dual-pathway approach to inflammatory bowel disease treatment.

Welcome to The BioPharm Brief, your daily snapshot of the biggest developments shaping biopharma and advanced therapeutics.

Today, we’re looking at three stories highlighting where innovation is accelerating across oncology, manufacturing science, and immunology.

First, Harbour BioMed has received FDA clearance to begin a Phase I clinical trial for HBM7004, a B7H4xCD3 bispecific antibody designed for advanced solid tumors. The investigational therapy works by redirecting T cells toward tumor cells expressing the B7H4 immune checkpoint protein. Bispecific antibodies continue to gain momentum in oncology because they can engage immune cells directly at the tumor site, potentially improving anti-cancer activity while reducing systemic toxicity. The company says preclinical studies showed encouraging anti-tumor activity and favorable safety signals.

Next, Merck published new research describing a scalable biocatalytic manufacturing process for enlicitide decanoate, its investigational oral PCSK9 inhibitor for lowering LDL cholesterol. Macrocyclic peptide therapies have historically faced manufacturing and scalability challenges, but Merck’s approach uses engineered enzymes and crystallization-based purification to improve efficiency. The work could have implications beyond cardiovascular disease, potentially supporting broader development of oral peptide therapeutics.

And finally, Johnson & Johnson released Phase 2b data for its investigational co-antibody therapy JNJ-4804 in refractory inflammatory bowel disease. The therapy simultaneously targets IL-23 and TNF-alpha, two major inflammatory pathways involved in ulcerative colitis and Crohn’s disease. Early data showed improved remission and endoscopic response rates in heavily treatment-experienced patients, reflecting growing industry interest in dual-pathway immune modulation strategies.

Thanks for listening to The BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Summary of Key Developments

  • Harbour BioMed advanced its B7H4xCD3 bispecific antibody into first-in-human clinical testing for solid tumors.
  • Merck reported a scalable enzyme-enabled manufacturing process for oral macrocyclic peptide therapeutics
  • Johnson & Johnson’s dual-pathway IBD therapy showed encouraging Phase 2b efficacy in refractory disease populations.

Related to this article

View more
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Read more
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
Read more
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
Read more
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.
Read more
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
The BioPharm Brief: Ivonescimab Priority Review in China, Stargardt Gene Therapy Moves Toward Phase 3, and Longer Dosing Intervals for an IBD Bispecific
China’s NMPA grants priority review to Akeso’s PD-1/VEGF bispecific ivonescimab with chemotherapy for first-line biliary tract cancer, VeonGen Therapeutics aligns with FDA on a phase 3 design for its dual-AAV Stargardt gene therapy VG801, and Caldera Therapeutics’ IL-23p19×TL1A bispecific CLD-423 shows a half-life of more than 40 days in a phase 1a trial.
Read more
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
The BioPharm Brief: A $7 Billion Oncology Option Deal, a TL1A Pivot, and Oral Adalimumab Heads to the Clinic
Boehringer Ingelheim licenses six preclinical ADC and T-cell engager programs from Sino Biopharmaceutical in a deal worth up to $7 billion, Spyre Therapeutics drops anti-TL1A antibody SPY072 in rheumatic diseases after phase 2 misses and turns to hidradenitis suppurativa, and Biora Therapeutics gets ethics approval for a first-in-human trial of its BioJet oral adalimumab capsule.
Read more